0
Skip to Content
Huygens & Versteegh
Publications
Contact
HTA news
Huygens & Versteegh
Publications
Contact
HTA news
Publications
Contact
HTA news

105P prognostic value of the NTRK fusion biomarker in the Netherlands

personalised medicineAnnals of Oncology
Sep 1
Written by Matthijs Versteegh
personalized medicine
Matthijs Versteegh
Previous
Previous

The potential impact of digial biomarkers in multiple slerosis in the Netherlands: an early HTA technology assessment of MS Sherpa
Next
Next

Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis

Huygens & Versteegh B.V.
Chamber of commerce: 85221155
Contact